Literature DB >> 29684672

Epigenetic modulation by small molecule compounds for neurodegenerative disorders.

Akash Kumar Singh1, Sarmistha Halder-Sinha1, James P Clement2, Tapas K Kundu3.   

Abstract

The accumulation of somatic and genetic mutations which altered the structure and coding information of the DNA are the major cause of neurological disorders. However, our recent understanding of molecular mechanisms of 'epigenetic' phenomenon reveals that the modifications of chromatin play a significant role in the development and severity of neurological disorders. These epigenetic processes are dynamic and reversible as compared to genetic ablations which are stable and irreversible. Therefore, targeting these epigenetic processes through small molecule modulators are of great therapeutic potential. To date, large number of small molecule modulators have been discovered which are capable of altering the brain pathology by targeting epigenetic enzymes. In this review, we shall put forward the key studies supporting the role of altered epigenetic processes in neurological disorders with especial emphasis on neurodegenerative disorders. A few small molecule modulators which have been shown to possess promising results in the animal model system of neurological disorders will also be discussed with future perspectives.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anacardic acid (PubChem CID:5388781); Blood-brain barrier; Cognitive brain function; DNA methylation; Decitabine (PubChem CID:451668); Embelin (PubChem CID:3218); Epigenetics; Histone acetylation; Luteolin (PubChem CID:5280445); Memory related disorders; Panobinostat (PubChem CID:6918837); RG108 (PubChem CID:702558); Romidepsine (PubChem CID:57515973); SAHA (PubChem CID:5311); Valproic acid (PubChem CID:3121); Vorinostat (PubChem CID:5311)

Mesh:

Year:  2018        PMID: 29684672     DOI: 10.1016/j.phrs.2018.04.014

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  7 in total

1.  Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid.

Authors:  Kanagaraj Subramanian; Darren M Hutt; Samantha M Scott; Vijay Gupta; Shu Mao; William E Balch
Journal:  J Biol Chem       Date:  2020-04-30       Impact factor: 5.157

Review 2.  Neurotransmitters-Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System.

Authors:  Raluca Ioana Teleanu; Adelina-Gabriela Niculescu; Eugenia Roza; Oana Vladâcenco; Alexandru Mihai Grumezescu; Daniel Mihai Teleanu
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

3.  Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease.

Authors:  Young-Kyoung Ryu; Hye-Yeon Park; Jun Go; Yong-Hoon Kim; Jung Hwan Hwang; Dong-Hee Choi; Jung-Ran Noh; Myungchull Rhee; Pyung-Lim Han; Chul-Ho Lee; Kyoung-Shim Kim
Journal:  J Neural Transm (Vienna)       Date:  2018-07-11       Impact factor: 3.575

4.  Advances in Nutritional Epigenetics-A Fresh Perspective for an Old Idea. Lessons Learned, Limitations, and Future Directions.

Authors:  Lynda Sedley
Journal:  Epigenet Insights       Date:  2020-12-18

5.  A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity.

Authors:  Hongxuan Feng; Xin Hu; Xin Sun; Wang Zheng; Houda G Khaled; Pan P Li; Dobrila D Rudnicki; Wenjuan Ye; Yu-Chi Chen; Noel Southall; Juan Marugan; Christopher A Ross; Marc Ferrer; Mark J Henderson; Russell L Margolis
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

6.  Glucose derived carbon nanosphere (CSP) conjugated TTK21, an activator of the histone acetyltransferases CBP/p300, ameliorates amyloid-beta 1-42 induced deficits in plasticity and associativity in hippocampal CA1 pyramidal neurons.

Authors:  Akash K Singh; Sin H Neo; Christine Liwang; Karen K L Pang; Jason C K Leng; Sarmistha H Sinha; Mahesh S Shetty; Madavan Vasudevan; Vinay J Rao; Ila Joshi; Muthusamy Eswaramoorthy; Maria V Pavon; Ang R Sheila; Sheeja Navakkode; Tapas K Kundu; Sreedharan Sajikumar
Journal:  Aging Cell       Date:  2022-08-12       Impact factor: 11.005

7.  Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model.

Authors:  Morgan J Homan; Andrea Franson; Karthik Ravi; Holly Roberts; Manjunath P Pai; Cai Liu; Miao He; Aleksas Matvekas; Carl Koschmann; Bernard L Marini
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-11       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.